AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
Category: Publication
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdfClémentine Spring-Giusti et al.American College of Toxicology – 40th Annual MeetingDownload the poster herePoster Presentation
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Poster 0710-AASLD 2019-TG1050-T101_MetaanalyseFabien Zoulim et al.AASLD 2019Download the poster herePoster Presentation
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication